AKT1 and Alzheimer disease: This spectrum of discordant perturbagens, which includes anti-inflammatory agents (quiflapon, zardaverine), metabolic regulators (AKT inhibitors), and neurotransmission modulators (moricizine, procaterol), underscores the potential for targeting diverse astrocyte-driven pathways in AD pathology beyond conventional neuron-focused approaches.